DGM
CCXI

Darwin Global Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Darwin Global Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-161,802
Closed -$5.89M – 12
2021
Q4 		$5.89M Buy
+161,802
New +$5.68M 0.9% 10

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Darwin Global Management's CCXI Position: Q1 2022 in Review

Darwin Global Management sold out of ChemoCentryx, Inc. (CCXI) in Q1 2022, closing a stake of 161,802 shares — an estimated $5.89M sold.

Darwin Global Management first reported a position in CCXI in Q4 2021 and held it in 1 quarter. The position peaked at $5.89M in Q4 2021. 176 funds tracked by Wall St. Rank hold CCXI as of Q1 2022.

  • Darwin Global Management reported no remaining ChemoCentryx, Inc. position as of Q1 2022 after selling out during the quarter.
  • Darwin Global Management sold 161,802 ChemoCentryx, Inc. shares in Q1 2022, an estimated $5.89M.
  • Darwin Global Management first reported a position in ChemoCentryx, Inc. in Q4 2021 and held it in 1 quarter.
  • Darwin Global Management's ChemoCentryx, Inc. position peaked at $5.89M in Q4 2021.
  • 176 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2022.

Based on Darwin Global Management's 13F filing for Q1 2022, filed 16 May 2022.